Table 1.

Clinical characteristic of 10 AML patients and their CI values

Patient ID	Sex	Age (years)	FAB	Karyotype	FLT3	NPM1	PRL-3 status*	Average CI values
Pt#1	M	44	M5	47,XY,+8	FLT3-ITD	WT	35	0.29
Pt#2	M	70	M4	Normal	WT	N.A.	21	0.35
Pt#3	F	34	M4	Inv(16)(p13.1q22)	N.A.	N.A.	23	0.33
Pt#4	M	62	M3	add(14)(q24)	FLT3-ITD	Mutant	19	0.47
Pt#5	F	41	M2	Normal	FLT3-ITD	Mutant	15	0.68
Pt#6	F	37	M5	Normal	WT	N.A.	0.8	1.31
Pt#7	M	33	M4	t(3;7)(p25;q22)	N.A.	N.A.	1.9	0.96
Pt#8	F	75	M2	Normal	WT	N.A.	1.3	1.20
Pt#9	M	26	M0	Complex	WT	WT	0.7	1.45
Pt#10	F	68	M2	Normal	WT	Mutant	1.8	0.98

Pt# indicates unique patient number

FAB French-American-British, Normal normal karyotype, FLT3 FMS-like tyrosine kinase 3, ITD internal tandem duplication, NPM1 nucleophosmin 1, N.A. not available, WT wild type, CI combination index

*qRT-PCR analysis was applied to determine the expression of PRL-3 gene in a serial of primary AML samples. The baseline expression of PRL-3 in OCI-AML2 was used to normalize the fold changes of PRL-3 gene in primary AML cells. Here, patients with PRL-3 expression more than 10fold higher than its expression in OCI-AML2 cells were defined as PRL-3 high, while for patients whose PRL-3 expression were less than twofold higher or lower than its expression in OCI-AML2 cells, they were classified as PRL-3 low